Clinical Study
Long-Term and Short-Term Effects of Hemodialysis on Liver Function Evaluated Using the Galactose Single-Point Test
Table 1
The demographic data and biochemistry parameters of the patients in the study (
).
| | Variables | Values | Value of reference |
| | Demographics | | | | Age (years) | 60.38 ± 11.86 | | | Female (%) | 28 (37.84) | | | Hepatitis B carrier (%) | 6 (8.18) | | | Hepatitis C carrier (%) | 4 (5.40) | | | Predialysis body weight (kg) | 62.50 ± 9.89 | | | Etiology of end-stage renal disease | | | | Diabetes mellitus | 14 (18.9%) | | | Polycystic kidney disease | 2 (2.7%) | | | Preclampsia | 1 (1.4%) | | | Cormobidity | | | | Hypertension | 16 (21.6%) | | | Coronary artery disease | 16 (21.6%) | | | Malignancy | 5 (6.75%) | | | Medication | | | | ACEi/ARB | 9 (12.1%) | | | Statin | 2 (2.7%) | | | Phosphate binder | 39 (52.7%) | | | Acetaminophen | 11 (14.8%) | | | Phenytoin | 2 (2.7%) | | | Rifampicin | 1 (1.4%) | | | Biochemistry parameters | | | | Glucose (mg/dL) | 124.83 ± 68.45 | 90–105 | | AST (U/L) | 22.19 ± 17.04 | 40 | | ALT (U/L) | 18.47 ± 15.38 | 40 | | Alk-p (U/L) | 78.07 ± 56.28 | 30–95 | | Albumin (g/dL) | 4.05 ± 0.35 | 3.5–5.0 | | Uric acid (mg/dL) | 7.24 ± 1.19 | 4.0–6.2 |
| | Variables | Values | |
| | Cr (mg/dL) | | | | Predialysis | 11.42 ± 2.02 | | | Postdialysis | 4.49 ± 3.32 | | | BUN (mg/dL) | | | | Predialysis | 72.71 ± 21.51 | | | Postdialysis | 19.13 ± 8.88 | | | Hematocrit (%) | | | | Predialysis | 28.60 ± 5.60 | | | Post-dialysis | 29.62 ± 6.26 | | | Months of Dialysis (months) | 60.77 ± 48.23 | | | Pre-dialysis GSP (g/mL) | 457.94 ± 297.83 | |
|
|
Note: = valid cases, AST = Aspartate transaminase, ALT = alanine aminotransferase, Cr = serum creatinine, BUN = blood urea nitrogen, alk-p = alkaline phosphatase, GSP = galactose single point.
|
